[go: up one dir, main page]

KR900702370A - Treatment and Diagnostic Method Using Soluble T Cell Surface Molecules - Google Patents

Treatment and Diagnostic Method Using Soluble T Cell Surface Molecules

Info

Publication number
KR900702370A
KR900702370A KR1019900701202A KR900701202A KR900702370A KR 900702370 A KR900702370 A KR 900702370A KR 1019900701202 A KR1019900701202 A KR 1019900701202A KR 900701202 A KR900701202 A KR 900701202A KR 900702370 A KR900702370 A KR 900702370A
Authority
KR
South Korea
Prior art keywords
antibody
monoclonal antibody
measuring
patient
monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019900701202A
Other languages
Korean (ko)
Inventor
패트릭 씨. 검
스테펜 에이취 입
마이클 씨 브라운
린다 에이 맥킨
Original Assignee
제임스 디. 그랜트
티 셀 사이언시스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 디. 그랜트, 티 셀 사이언시스 인코포레이티드 filed Critical 제임스 디. 그랜트
Publication of KR900702370A publication Critical patent/KR900702370A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553—Metal or metal coated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음No content

Description

가용성 T세포 표면분자를 사용하는 치료 및 진단방법.Therapeutic and diagnostic methods using soluble T cell surface molecules.

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 정상인과 다수의 질병그룹에서 택한 환자의 혈청에든 가용성 CD4이 레벨, 사용된 검사법은 다음의 6, 2, 2항에서 기술하였다. CD4항원은 샌드위치 면역검사법에서 포획시약으로서 mAb 8F4를 그리고 검출시약으로서 mAb R2B7를 사용하여 검출하였다. 검사법의 민감도의 한계는 20단위이였다. 제2도는 정상인과 여러질병 그룹에서 택한 환자의 가용성 CD4의 레벨을 나타낸다. 사용된 검사법은 다음의 6, 2, 2항에서 기술한 것과 같다. SF:활액 EBV/mono:Epstein Barr 비루스/모노핵증식. 제3도는 카포시육종이나 또는 AIDS관련된 복합체(ARC)가 있는 환자의 혈청에든 가용성 CD8레벨의 세로방향 연구, 닫힌 다이아몬드: 가용성 CD8레벨(U/ml); 열린 다이아몬드:HIV p24 레벨(pg/ml)x10.Figure 1 shows the levels of soluble CD4 in serum of normal subjects and patients selected from a number of disease groups, and the assays used are described in Sections 6, 2, and 2 below. CD4 antigen was detected in the sandwich immunoassay using mAb 8F4 as capture reagent and mAb R2B7 as detection reagent. The sensitivity limit of the test was 20 units. 2 shows the levels of soluble CD4 in patients selected from normal and multiple disease groups. The test method used is as described in 6, 2 and 2 below. SF: Synovial EBV / mono: Epstein Barr virus / mononucleus proliferation. 3 is a longitudinal study of soluble CD8 levels in serum of patients with Kaposi's sarcoma or AIDS related complex (ARC), closed diamond: soluble CD8 level (U / ml); Open diamond: HIV p24 level (pg / ml) × 10.

Claims (62)

(a)면역특이성 결합을 허용하는 조건에서 CD4 항원에서 제1항-CD4 부위와 같은 결합 부위에 대한 경쟁을 하지 않는 제2항-CD4 단일클론의 항체와 제1항-CD4 단이를론의 항체를 가진 시료를 접촉시키고: 그리고 (b)제1및 제2항-CD4 항체의 두가지 모두를 가진 시료에서 성분의 면역특이성 결합이 발생하는지를 검출하고, 이때 제1및 제2항-CD4 항체의 두가지 모두를 가진 시료의 성분의 면역특이성 결합이 가용성분자의 존재를 나타내는, 단계를 포함하고 시료는 자발적으로 방출되는 것같은 가용성 분자만을 포함하는 CD4 T세포 표면 항원성 결정인자를 수반 하는 가용성 분자의 시표에든 양의 검출 또는 측정 방법.(a) an antibody of claim 2 -CD4 monoclonal and an antibody of claim 1 -CD4 monoislon that does not compete for binding sites, such as the claim 1 -CD4 site, in the CD4 antigen under conditions that allow immunospecific binding Contacting a sample with: (b) detecting whether an immunospecific binding of the component occurs in a sample with both the first and second anti-CD4 antibodies, wherein the two of the first and second anti-CD4 antibodies Specification of a soluble molecule involving CD4 T cell surface antigenic determinants, comprising a step wherein the immunospecific binding of the components of the sample with all indicates the presence of soluble molecules and the sample contains only soluble molecules that are likely to be spontaneously released Method of detecting or measuring edin amount. 제1항에 있어서, 제2항체가 검출가능한 신호를 만들 수 있도록 라벨이된 방법.The method of claim 1, wherein the second antibody is labeled to produce a detectable signal. 제1항에 있어서, 제1항체를 고정시킨 방법.The method of claim 1 wherein the first antibody is immobilized. 제1항에 있어서, 제1항체를 고정시키고 제2항체는 면역특이성 결합이 고정된 라벨의 검출로 나타나도록 라벨을 한방법.The method of claim 1, wherein the first antibody is immobilized and the second antibody is labeled so as to result in detection of a label having immobilized immunospecific binding. 제1,2 또는 4항에 있어서, 제1항체가 기탁번호 HB 9843호를 ATCC에 기탁한 하이브리도마로서 만든것 같은 단일클론의 항체를 포함하는 방법.The method according to claim 1, 2 or 4, wherein the first antibody comprises a monoclonal antibody, such as one which has been made as hybridoma deposited Accession No. HB 9843 to ATCC. 제1,2 또는 4항에 있어서, 제1항체가 기탁번호 HB 9842호로서 ATCC에 기탁한 하이브리도마로 만든것 같은 단일클론의 항체 R2B7를 포함하는 방법.The method of claim 1, 2 or 4, wherein the first antibody comprises a monoclonal antibody R2B7, such as made from a hybridoma deposited with ATCC as Accession No. HB 9842. 6. 제1,2 또는 4항에 있어서, 제1항체가 기탁번호 HB 9843호로 ATCC에 기탁한 하이브리도마로 생성한 단일클론의 항체 8F4를 포함하고, 제2항체 기탁번호 HB 9842로 ATCC에 기탁한 하이브리도마로서 생성한 단일클론의 항체 R2B7를 포함하는방법.The antibody of claim 1, 2 or 4, wherein the first antibody comprises monoclonal antibody 8F4 produced by hybridoma deposited with ATCC under Accession No. HB 9843, and deposited with ATCC under Antibody No. HB 9842. A method comprising a monoclonal antibody R2B7 produced as a hybridoma. 제1항에 있어서, 제1항체가 기탁번호 HB 9843호로 ATCC에 기탁한 하이브리도마로 생성한 단일클론의 항체 8F4와 같은 에피토프 특이성을 가지는 방법.The method of claim 1, wherein the first antibody has the same epitope specificity as the monoclonal antibody 8F4 produced by hybridoma deposited with ATCC under Accession No. HB 9843. 제1항에 있어서, 제2항체가 기탁번호 HB 9842호로 ATCC에 기탁한 하이브리도마로 생성한 단일클론의 항체 R2B7과 같은 에피토프 특이성을 가지는 방법.The method of claim 1, wherein the second antibody has the same epitope specificity as the monoclonal antibody R2B7 produced by hybridoma deposited with ATCC under Accession No. HB 9842. 제1항에 있어서, 제1항체가 기탁번호 HB 9843호로 ATCC에 기탁한 하이브리도마로 생성된 단일클론의 항체 8F4와 같은 에피토프 특이성을 가지고 제2항체 기탁번호 HB 9842호로서 ATCC에 기탁한 하이브리도마를 생성한 단일클론의 항체 R2B7과 같은 에피토프 특이성을 가지는 방법.The high antibody deposited with ATCC as antibody No. HB 9842 with the same epitope specificity as the monoclonal antibody 8F4 produced by hybridoma deposited with ATCC under Accession No. HB 9843. A method having the same epitope specificity as the monoclonal antibody R2B7 producing bridoma. 제1항 또는 제4항에 있어서, 시료가 혈청인 방법.The method of claim 1 or 4, wherein the sample is serum. (a)제1항-CD4 단일클론의 항체: 및 (b)CD4 항원에서 제1항-CD4 항체와 같은 결합부위에 대해 경쟁치 않는 제2항-CD4 단일클론의 항체를 포함하는 CD4 세포 표면 항원의 세포없는 가용성 분자 수반 항원성 결정 인자의 레벨을 측정하는 키트.(a) an antibody of claim 1 -CD4 monoclonal: and (b) a CD4 cell surface comprising an antibody of claim 2 -CD4 monoclonal that does not compete for binding sites such as the claim 1 -CD4 antibody in the CD4 antigen Kit for measuring the level of antigenic determinants involving cell-free soluble molecules of an antigen. 제12항에 있어서, 제2항-CD4 항체를 검출신호를 만들 수 있도록 라벨을 하는 키트.The kit of claim 12, wherein the kit is labeled to generate a detection signal. 제13항에 있어서, 라벨이 효소인 키트.The kit of claim 13, wherein the label is an enzyme. 제14항에 있어서, 효소가 고추냉이 과산화효소인 키트.The kit of claim 14, wherein the enzyme is horseradish peroxidase. 제12항에 있어서, 제1항체가 기탁번호 HB 9843호로 ATCC에 기탁한 하이브리도마로 생성한 것같은 단일클론의 항체 8F4를 포함하는 키트.The kit of claim 12, wherein the first antibody comprises a monoclonal antibody 8F4 as produced by hybridoma deposited with ATCC under Accession No. HB 9843. 제12항에 있어서, 제2항체가 기탁번호 HB 9842호로 ATCC에 기탁한 하이브리도마로 생성한 것같은 단일클론의 항체 R2B7를 포함하는 키트.The kit of claim 12, wherein the second antibody comprises a monoclonal antibody R2B7 as produced by hybridoma deposited with ATCC under Accession No. HB 9842. 제12항에 있어서, 제1항체가 기탁번호 HB 9843호로 ATCC에 기탁한 하이브리도마로 생성한 단일클론의 항체 8F4를 포함하고 제2항체가 기탁번호 HB 9842호로 ATCC에 기탁한 하이브리도마로 생성한 단일클론의 항체 R2B7를 포함하는 키트.13. The hybridoma according to claim 12, wherein the first antibody comprises monoclonal antibody 8F4 produced by hybridoma deposited with ATCC under accession number HB 9843 and the second antibody deposited with ATCC under accession number HB 9842. Kit comprising the resulting monoclonal antibody R2B7. 제17항에 있어서, 단일클론의 항체 R2B7을 라벨하는 키트.18. The kit of claim 17, wherein the antibody labels a monoclonal antibody R2B7. 제18항에 있어서, 단일클론의 항체 R2B7을 라벨하는 항체.The antibody of claim 18, wherein the antibody labels a monoclonal antibody R2B7. 제20항에 있어서, 라벨이 효소인 키트.The kit of claim 20 wherein the label is an enzyme. 제21항에 있어서, 효소가 고추냉이 과산화효소인 키트.The kit of claim 21 wherein the enzyme is horseradish peroxidase. 제12항에 있어서, 제1항체가 기탁번호 HB 9843호를 ATCC에 기탁한 하이브리도마로 생성한 단일클론의 항체 8F4와 같은 에피토프 특이성을 가지는 키트.The kit of claim 12, wherein the first antibody has the same epitope specificity as the monoclonal antibody 8F4 produced with hybridoma deposited Accession No. HB 9843 to ATCC. 제12항에 있어서, 제2항체가 기탁번호 HB 9842호로 ATCC에 기탁한 하이브리도마로 생성된 단일클론의 항체 R2B7과 같은 에피토프 특이성을 가지는 키트.The kit of claim 12, wherein the second antibody has the same epitope specificity as the monoclonal antibody R2B7 produced by hybridoma deposited with ATCC under accession no. HB 9842. 제12항에 있어서, 제1항체가 기탁번호 HB 9843호로 ATCC에 기탁한 하이브리도마로 생성된 단일클론의 항체 8F4와 같은 에피토프 특이성을 가지고 제2항체 기탁번호 HB 9842호로 ATCC에 기탁한 하이브리도마를 생성한 단일클론의 항체 R2B7과 같은 에피토프 특이성을 가지는 키트.13. The hybrid of claim 12, wherein the first antibody has the same epitope specificity as the monoclonal antibody 8F4 produced by hybridoma deposited with ATCC under Accession No. HB 9843 and deposited with ATCC under Antibody No. HB 9842. A kit having the same epitope specificity as the monoclonal antibody R2B7 producing the chopping board. 피검자에서 취한 시료에 CD4 T 세포표면 항원의 자발적으로 방출된 가용성 분자를 수반하는 항원성 결정 인자의 양으로 비활성화한 상태의 피검자의 레벨에 대해서 증가를 검출하거나 측정하는 것을 포함하는 피검자의 면역 활성화 상태의 진단방법.Immune activation state of the subject, comprising detecting or measuring an increase in the level of the subject inactivated in the amount of antigenic determinants accompanied by spontaneously released soluble molecules of CD4 T cell surface antigen in the sample taken from the subject Method of diagnosis. 피검자에서 취한 시료에 제1항의 방법으로 CD4 T세포표면 항원의 자발적으로 방출된 가용성 분자를 수반하는 항원성 결정인자의 양으로 비활성화한 상태의 피검자의 레벨에 대해서 증가를 검출하거나 측정하는 것을 포함하는 피검자의 면역 활성화 상태의 진단방법.Detecting or measuring an increase in the level of the subject inactivated by the amount of antigenic determinants accompanying the spontaneously released soluble molecules of the CD4 T cell surface antigen to the sample taken from the subject. Method of diagnosing the immune activation state of a subject. 피검자에서 취한 시료에 제7항의 방법에 따른 CD4 T세포표면 항원의 자발적으로 방출된 가용성 분자를 수반하는 항원성 결정인자의 양으로 비활성화한 상태의 피검자의 레벨에 대해서 증가를 검출하거나 측정하는 것을 포함하는 피검자의 면역 활성화 상태의 진단방법.Detecting or measuring an increase in the level of the subject inactivated by the amount of antigenic determinants accompanying the spontaneously released soluble molecules of the CD4 T cell surface antigen according to the method of claim 7 to the sample taken from the subject. A method for diagnosing the immune activation state of a subject. T세포 생체외에서 배양하고 그리고 세포배양유체의 시로에서 CD4 T 세포 표면 항원의 자발적으로 방출된 가용성 분자를 수반하는 항원성 검출인자의 양을 검출하거나 측정하는 것을 포함하는 T세포의 표현형의 측정방법.A method for measuring the phenotype of T cells, comprising culturing the T cells ex vivo and detecting or measuring the amount of antigenic detection factors involving the spontaneously released soluble molecules of CD4 T cell surface antigens in the cell culture fluid. 환자에서 취한 시료에든 CD4 T세포 표면항원의 자발적으로 방출된 가용성 분자를 수반하는 항원성 결정 인자의 양을 측정하는 것을 포함하는 조기에 환자나 건강인에 대한 양의 증가가 질병의 더욱 진전된 기를 나타내는 환자의 성인 T세포 백혈병의 기측정방법.Early increases in the amount of the patient or healthy person, including measuring the amount of antigenic determinants involving the spontaneously released soluble molecules of CD4 T cell surface antigens in the sample taken from the patient, may lead to further development of the disease. Method of measuring the adult T-cell leukemia of the patient. 제30항에 있어서, 시료가 혈청인 방법.The method of claim 30, wherein the sample is serum. 조기에 환자나 건강면에 대해서 환자에서 취한 활액에든 CD4 T세포 표면항원의 자발적으로 방출된 가용성 분자수반 항원성 결정 인자의 양의 증가를 검출하거나 측정하는 것을 포함하는 환자의 유류마티스 관점염의 진단방법.A method of diagnosing rheumatoid arthritis in a patient, comprising detecting or measuring an increase in the amount of spontaneously released soluble molecule-associated antigenic determinants of CD4 T cell surface antigens in the synovial fluid taken from the patient for the patient or health aspects early on . CD4 T세포 표면항원의 자발적으로 방출된 가용성 분자수반 항원성 결정인자의 혈청에든 양에 대해서 활액의 양의 증가를 검출하거나 측정하는 것을 포함하는 환자의 유류마티스 관절염의 진단방법.A method for diagnosing rheumatoid arthritis in a patient, comprising detecting or measuring an increase in the amount of synovial fluid relative to the serum in the spontaneously released soluble molecular accompanying antigenic determinant of CD4 T cell surface antigen. 환자의 체액에든 CD4 T세포 표면항원의 자발적으로 방출된 가용성의 분자수반 항원성 결정인자의 레벨을 측정하는 것을 포함하는 비루스 감염된 환자의 치료를 감시하는 방법.A method of monitoring the treatment of a virally infected patient comprising measuring the level of spontaneously released soluble molecular accompanying antigenic determinants of CD4 T cell surface antigen in the body fluids of the patient. 제34항에 있어서, 비루스 감염이 사람 면역 결핍 비루스 감염인 방법.The method of claim 34, wherein the virus infection is a human immunodeficiency virus infection. CD4 T세포 표면 항원에 대해서, CD4 T세포 표면 항원의 자발적으로 방출된 가용성의 분자를 수반하는 항원성 결정인자에 바람직하게 결합하는 단일클론의 항체.A monoclonal antibody, which preferably binds to a CD4 T cell surface antigen, preferably to an antigenic determinant carrying a spontaneously released soluble molecule of the CD4 T cell surface antigen. (a) CD4 T세포 표면 항원의 자발적으로 방출된 가용성 분자 수반 항원성 결정인자와 그리고 (b) CD4 T 세포 표면 항원과 반응성이 있는 쥐의 단일클론의 항체.(a) Mouse monoclonal antibodies of spontaneously released soluble molecules carrying antigenic determinants of CD4 T cell surface antigens and (b) reactive with CD4 T cell surface antigens. 기탁번호 HB 9843으로 ATCC에 기탁한 하이브리도마를 생성한 단일 클론의 항체 8F4.Monoclonal antibody 8F4 which produced hybridoma deposited with ATCC under accession no. HB 9843. 기탁번호 HB 9842으로 ATCC에 기탁한 하이브리도마를 생성된 단일 클론의 항체 R2B7.Monoclonal antibody R2B7 resulting from hybridomas deposited with ATCC under accession number HB 9842. 제36,37,38 또는 39항의 단일클론의 항체의 Fv, Fab, Fab′또는 F(ab′)₂ 단편.Fv, Fab, Fab 'or F (ab') 2 fragment of the monoclonal antibody of claim 36,37,38 or 39. 제36,37,38 또는 39항의 단일클론의 항체의 Fv, Fab,Fab′ 또는 F(ab′)₂ 단편을 포함하는 항체.An antibody comprising the Fv, Fab, Fab 'or F (ab') 2 fragment of the monoclonal antibody of claim 36, 37, 38 or 39. (a) 이식환자에서 취한 시료에든 인터로이킨-2 수용체의 자발적으로 방출된 가용성 분자를 수반하는 항원성 결정 인자의 양을 측정하고: (b)판자에서 취한 체액에든 크라아티닌의 양을 측정하는 것을 포함하고, 이때 이식이 없거나 거부를 내지 않는 건강한 피검자에 대해서나 또는 조기의 환자에 대해서 크레아티닌과 분자의 모두의 양의 증가각 이인자형 이식의 거부를 나타내는 이식에서 감염으로 부터의 이인자형 거부를 감별식으로 진단하는 방법.(a) Determining the amount of antigenic determinants involving spontaneously released soluble molecules of the interleukin-2 receptor in a sample taken from a transplant patient: (b) Determining the amount of creatinine in body fluids taken from the plate Increase in the amount of both creatinine and molecule for healthy subjects who do not have or do not reject the transplant, or for early patients. How to diagnose differentially. 제42항에 있어서, 시료가 혈청을 포함하고 체액이 혈청을 포함 하는 방법.43. The method of claim 42, wherein the sample comprises serum and the body fluid comprises serum. 제42항에 있어서, 시료가 뇨를 포함하고, 체액이 뇨를 포함하는 방법.43. The method of claim 42, wherein the sample comprises urine and the body fluid comprises urine. 제42항에 있어서, (a)면역특이성 결합을 허용하는 조건에서 기탁번호 HB 9841로 ATCC에 기탁한 하이브리도마를 생성한 단일클론의 항체 2R12를 가지고, 기탁번호 HB 8784로서 ATCC에 기탁한 하이브리도마를 생성한 단일클론의 항체 7G7를 가진 시료를 접촉시키고, 그리고 (b)단일클론의 항체 2R12은 7G7의 둘 모두를 가진 시료에든 성분의 면역 특이성 결합의 발생여부를 측정하는 것으로서, 인터로이킨-2 수용체의 가용성 분자수반 항원성 결정인자를 검출하고 이때 이러한 면역특이성 결합이 시료중의 가용성 분자의 존재를 나타내는 방법.43. The antibody according to claim 42, wherein (a) has a monoclonal antibody 2R12 that yields a hybridoma deposited with ATCC under accession number HB 9841 under conditions permitting immunospecific binding, and the high deposited with ATCC as accession number HB 8784. Contacting a sample with a monoclonal antibody 7G7 producing bridoma, and (b) monoclonal antibody 2R12 is a measure of the incidence of immunospecific binding of components in a sample with both 7G7, interleukin Soluble molecule-associated antigenic determinants of the -2 receptor, wherein such immunospecific binding indicates the presence of soluble molecules in the sample. 제42항에 있어서, 이인자형 콩팥 이식을 포함하는 방법.43. The method of claim 42, comprising two-factor renal transplantation. 제42항에 있어서, 이인자형 이식이 심장이식을 포함하는 방법.43. The method of claim 42, wherein the two-factor transplantation comprises heart transplantation. 환자의 체액에서 다수의 자발적으로 방출된 가용성 분자의 레벨을 측정하는 것을 포함하고, 이 분자는 인터로이킨-2 수용체의 분자 수반 항원성 결정인자, CD4 항원의 분자수반 항원성 결정인자 및 CD8 항원의 분자수반 항원성 결정인자로 구성된 그룹에서 선택되는 환자의 질병이나 질환의 치료의 검출 감시 또는 기를 측정하는 방법.Measuring the level of a number of spontaneously released soluble molecules in the body fluids of the patient, the molecules comprising the molecular accompanying antigenic determinants of the interleukin-2 receptor, the molecular accompanying antigenic determinants of the CD4 antigen and the CD8 antigen. A method of detecting, monitoring, or measuring the detection of a disease or treatment of a patient selected from the group consisting of molecular accompanying antigenic determinants. 제48항에 있어서, 건강인이나 또는 조기의 환자의 레벨에 대해서 분자의 레벨의 변화를 측정하는 것을 포함하는 방법.49. The method of claim 48, comprising measuring a change in the level of the molecule relative to the level of a healthy person or an early patient. 제48항에 있어서, 질병이나 질환이 이식거부를 포함하는 방법.49. The method of claim 48, wherein the disease or condition comprises transplant rejection. 제49항에 있어서, 질병이나 질환이 이식거부를 포함하는 방법.The method of claim 49, wherein the disease or condition comprises transplant rejection. 제50항에 있어서, 이식이 콩팥이식인 방법.51. The method of claim 50, wherein the transplant is kidney transplantation. 제52항에 있어서, 콩팥이식 거부를 시클로스포린A 독성으로 감별 진단하는 방법.The method of claim 52, wherein the kidney transplant rejection is differentially diagnosed with cyclosporin A toxicity. 제48항에 있어서, 질병이나 질환이 비루스 감염으로 되는 방법.49. The method of claim 48, wherein the disease or condition is a viral infection. 제49항에 있어서, 질병이나 질환이 비루스 감염으로 되는 방법.The method of claim 49, wherein the disease or condition is a viral infection. 제54항 또는 55항에 있어서, 비루스 감염이 사람면역 결핍 비루스 감염인 방법.The method of claim 54 or 55, wherein the virus infection is a human immunodeficiency virus virus infection. 제48항에 있어서, 질병이나 질환이 유류마티스 관절염을 포함하는 방법.49. The method of claim 48, wherein the disease or condition comprises rheumatoid arthritis. 제49항에 있어서, 질병이나 질환이 유류마티스 관절염을 포함하는 방법.The method of claim 49, wherein the disease or condition comprises rheumatoid arthritis. (a) 한쌍의 항-인터로이킨-2-수용체 단일클론의 항체,이 항체는 인토로이킨-2-수용체의 같은 결합부위에서 경쟁하지 않으며, (b)한쌍의 항-CD4 단일클론의 항체, 이항체는 CD4 항원에서 같은 결합부위에 대해서 경쟁하지 않는 것을 포함하는 환자의 질병이나 질환의 치료의 검출, 감시 또는 기의 측정 방법.(a) a pair of anti-interleukin-2-receptor monoclonal antibodies, which do not compete in the same binding site of the intorokin-2-receptor, (b) a pair of anti-CD4 monoclonal antibodies, binomial A method of detecting, monitoring, or measuring a group of diseases or disorders in a patient, wherein the sieve does not compete for the same binding site in the CD4 antigen. (a) 한쌍의 항-인터로이킨-2-수용체 단일클론의 항체, 이 항체는 인토로이킨-2-수용체의 같은 결합부위에서 경쟁하지 않으며, (b)한쌍의 항-CD4 단일클론의 항체, 이항체는 CD4항원에서 같은 결합부위에 대해서 경쟁하지 않는 것을 포함하는 환자의 질병이나 치료의 치료의 검출, 감시 또는 기의 측정 방법.(a) a pair of anti-interleukin-2-receptor monoclonal antibodies, the antibodies do not compete in the same binding site of the intorokin-2-receptor, and (b) a pair of anti-CD4 monoclonal antibodies, binomial A method of detecting, monitoring, or measuring a group of diseases or treatments of a patient, wherein the sieve does not compete for the same binding site in the CD4 antigen. (a) 한쌍의 항-CD8 단일클론의 항체, 이 항체는 CD8 항원에서 같은 결합부위에서 경쟁하지 않으며,(b)한쌍의 항-CD4 단일클론의 항체, 이 항체는 CD4 항원에서 같은 결합부위에 대해서 경쟁하지 않는 것을 포함하는 환자의 질병이나 질환의 치료의 검출, 감시 또는 기의 측정 방법.(a) a pair of anti-CD8 monoclonal antibodies, the antibodies do not compete at the same binding site in the CD8 antigen, (b) a pair of anti-CD4 monoclonal antibodies, the antibody at the same binding site at the CD4 antigen A method of detecting, monitoring, or measuring a patient's disease or treatment, including those that do not compete for. 제59항에 있어서, 한쌍의 항-CD8 단일클론의 항체를 추가로 포함하고, 이 항체는 CD8항원에서 같은 결합부위에 대해 경쟁하지 않는 키트.60. The kit of claim 59, further comprising a pair of anti-CD8 monoclonal antibodies, wherein the antibodies do not compete for the same binding site in the CD8 antigen. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019900701202A 1988-10-06 1989-10-05 Treatment and Diagnostic Method Using Soluble T Cell Surface Molecules Ceased KR900702370A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25455188A 1988-10-06 1988-10-06
US254.551 1988-10-06
PCT/US1989/004413 WO1990004180A1 (en) 1988-10-06 1989-10-05 Therapeutic and diagnostic methods using soluble t cell surface molecules

Publications (1)

Publication Number Publication Date
KR900702370A true KR900702370A (en) 1990-12-06

Family

ID=22964717

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900701202A Ceased KR900702370A (en) 1988-10-06 1989-10-05 Treatment and Diagnostic Method Using Soluble T Cell Surface Molecules

Country Status (4)

Country Link
KR (1) KR900702370A (en)
AU (1) AU4416189A (en)
CA (1) CA2000308A1 (en)
WO (1) WO1990004180A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
JPH05504621A (en) * 1989-11-15 1993-07-15 ナショナル・ジューイッシュ・センター・フォア・イミュノロジー・アンド・レスピラトリー・メディスン Quantification method for human T cell surface antigen
US5527884A (en) * 1993-12-21 1996-06-18 President And Fellows Of Harvard College Mediators of chronic allograft rejection and DNA molecules encoding them
US5658745A (en) * 1995-02-17 1997-08-19 E. I. Du Pont De Nemours And Company Cell enumeration immunoassay
DE19821060A1 (en) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let T cell co-stimulating polypeptide, monoclonal antibodies, and the production and use thereof
AU752433B2 (en) * 1997-09-23 2002-09-19 Bundesrepublik Deutschland letzvertreten durch Den Direktor des Robert-Koch-Instituts Costimulating T-cell polypeptide, monoclonal antibodies, their preparation and use
JPH11271304A (en) * 1998-03-24 1999-10-08 Jcr Pharmaceuticals Co Ltd Hiv infection diagnosing method
US8318905B2 (en) 2004-04-23 2012-11-27 Richard Kroczek Antibodies for depletion of ICOS-positive cells in vivo
WO2013086462A1 (en) * 2011-12-09 2013-06-13 Sequenta, Inc. Method of measuring immune activation
EP2972387A1 (en) * 2013-03-15 2016-01-20 Westfälische Wilhelms-Universität Münster Detection of acute renal allograft rejection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707443A (en) * 1985-04-19 1987-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Soluble interleukin-2 receptor as a disease indicator and a method of assaying the same
DE3628718A1 (en) * 1985-12-03 1987-06-04 Bayer Ag RELEASED INTERLEUKIN-2 RECEPTORS AS AN INDICATOR FOR IMMUNE REACTIONS AND NEOPLASIA
US5006459A (en) * 1986-03-31 1991-04-09 T Cell Sciences, Inc. Therapeutic and diagnostic methods using soluble T cell surface molecules

Also Published As

Publication number Publication date
AU4416189A (en) 1990-05-01
WO1990004180A1 (en) 1990-04-19
CA2000308A1 (en) 1990-04-06

Similar Documents

Publication Publication Date Title
Schwartz et al. Human immunodeficiency virus test evaluation, performance, and use: Proposals to make good tests better
US4725669A (en) Assay for detecting infection by human T-cell lymphotropic virus-III
US4520113A (en) Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
US5705331A (en) HIV nucleocapsid protein capture assay and method of use
CA1283045C (en) Therapeutic and diagnostic methods using soluble t cell surface molecules
AU612686B2 (en) Monoclonal antibody specific to hiv antigens
JPH0692972B2 (en) HTLV-III III Immunoassay for Antigen
Shah et al. Serological investigation of BK papovavirus infection in pregnant women and their offspring
EP0151579A1 (en) METHOD AND PRODUCTS FOR DETECTION OF HUMAN T CELL LEUKEMIA VIRUS.
JPH0232261A (en) Immunoassay for detecting hivi antigen
KR900702370A (en) Treatment and Diagnostic Method Using Soluble T Cell Surface Molecules
Lu et al. Anti-gp160 IgG and IgA antibodies associated with a large increase in total IgG in cervicovaginal secretions from human immunodeficiency virus type 1-infected women
Yolken et al. Enzyme immunoassays for measurement of cytomegalovirus immunoglobulin M antibody
Glassy et al. An enzyme immunofiltration assay useful for detecting human monoclonal antibody
Rylatt et al. A rapid whole‐blood immunoassay system
Van Dyke et al. Mother-to-child transmission of human T-lymphotropic virus type II
Neumann et al. Laboratory diagnosis of the first cases of HIV-2 infection in Canada
WO1996028569A1 (en) Monoclonal antibody and antigen relating to human pulmonary adenocarcinoma and immunoassay method with the use of the same
Newman et al. Murine monoclonal antibody adsorbed onto vinylidene fluoride floccules used to eliminate antibody interference in" sandwich"-type immunoassays.
EP0308242B1 (en) Agglutination assay
Luo et al. Use of saliva as an alternative to serum for HIV screening in Africa
Berry et al. A comparison of four enzyme immunoassays for the simultaneous detection of HIV-1-and HIV-2-specific antibody
Mbopi-Keou et al. Differential influence of race and environment on indeterminate reactivities to non-treponemal and treponemal antigens by immunochromatographic dual syphilis rapid test
US5164293A (en) Monoclonal antibody for detecting HTLV-I, HTLV-II and STLV-I viruses
Armstrong et al. Prevalence of antibodies interactive with HTLV‐I antigens in selected Solomon Islands population

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19900607

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19940926

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19900607

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980115

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19980423

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19980115

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I